Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 4Sarcoma 2Lymphoid 2Head & Neck 2Genitourinary 2Endocrine 2Dermatologic 2Thoracic 1Other hematologic neoplasm 1NET 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Thyroid Cancer, Papillary 2Sarcoma 2Salivary Gland Neoplasms 2Brain Neoplasms 2Wilms Tumor 1Sarcoma, Ewing 1Recurrence 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1Nephroma, Mesoblastic 1Neoplasm Metastasis 1Melanoma 1Medulloblastoma 1Lymphoma, Large-Cell, Anaplastic 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1Cholangiocarcinoma 1Central Nervous System Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Advanced Thyroid Cancer Patients Who Received Target Therapy 1

Interventions

Magnetic Resonance Spectroscopy 3entrectinib 2Radiotherapy 2Proton Therapy 2Fluorodeoxyglucose F18 2FAPI-46 2tipifarnib 1pegvisomant 1fluorodopa F 18 1entinostat 1dactolisib 1alectinib 1Trastuzumab 1Tamoxifen 1Surveys and Questionnaires 1Specimen Handling 1Ritonavir 1Respiratory Therapy 1Radiation Dose Hypofractionation 1Quality of Life 1Protons 1Positron-Emission Tomography 1Photochemotherapy 1Patient Reported Outcome Measures 1Octreotide 1Neuropsychological Tests 1Molecular Diagnostic Techniques 1Indinavir 1Immunotherapy 1Furosemide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Brain Neoplasms × entrectinib × Endocrine × Clear all
NCT02568267 2026-05-27

STARTRK-2

Hoffmann-La Roche

Phase 2 Active not recruiting
534 enrolled 1 FDA
BreastCNSDermatologicEndocrineGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidNETSarcomaThoracic

Thyroid Cancer, Papillary, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Salivary Gland Neoplasms, Sarcoma, Colorectal Neoplasms, Lymphoma, Large-Cell, Anaplastic, Cholangiocarcinoma, Neuroendocrine Tumors

NCT02650401 2026-03-25

STARTRK-NG

Hoffmann-La Roche

Phase 1/2 Active not recruiting
69 enrolled 1 FDA
CNSEndocrineGenitourinaryHead & NeckSarcoma

Thyroid Cancer, Papillary, Brain Neoplasms, Glioma, Medulloblastoma, Neoplasm Metastasis, Wilms Tumor, Neuroblastoma, Recurrence, Salivary Gland Neoplasms, Sarcoma, Sarcoma, Ewing, Central Nervous System Neoplasms, Nephroma, Mesoblastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡